Δευτέρα 25 Απριλίου 2022

Canadian real-world study of access and clinical results using dupilumab for chronic rhinosinusitis with polyps

alexandrossfakianakis shared this article with you from Inoreader

40463.jpg

Dupilumab is the first monoclonal antibody therapy to be approved in Canada for the treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP). The goal of the study was to assess its effectiveness and eff...
View on the web

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Αρχειοθήκη ιστολογίου